Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSTUCKELMAN, Zachary D.
dc.contributor.authorMULQUEEN, Jilian M.
dc.contributor.authorFERRACIOLI-ODA, Eduardo
dc.contributor.authorCOHEN, Stephanie C.
dc.contributor.authorCOUGHLIN, Catherine G.
dc.contributor.authorLECKMAN, James F.
dc.contributor.authorBLOCH, Michael H.
dc.date.accessioned2017-10-24T13:23:02Z
dc.date.available2017-10-24T13:23:02Z
dc.date.issued2017
dc.description.abstractObjective: Irritability is listed as a common side effect of psychostimulant medications. However, psychostimulants have been demonstrated as an effective treatment in reducing irritability and aggression in children with attention-deficit/hyperactivity disorder (ADHD). The goal of this study was to quantify the risk of irritability as a side effect of psychostimulant treatment for ADHD. Data Sources and Study Selection: A PubMed search was conducted on August 18, 2013, to identify all double-blind, randomized, placebo-controlled trials published in English examining the efficacy of psychostimulant medications in the treatment of children with ADHD. Trials were excluded if (1) they required additional psychiatric or medical comorbidity in addition to ADHD, (2) they involved fewer than 20 subjects (parallel group trials), or (3) children received psychostimulant medication for less than 1 week. Data Extraction: A fixed-effects meta-analysis was used to examine the risk ratio of irritability reported as a side effect in children treated with psychostimulants compared to placebo. Stratified subgroup analysis and meta-regression were used to examine the effects of stimulant type, dosage, duration of use, and trial design on the measured risk of irritability. Results: From 92 potentially eligible trials, the meta-analysis identified 32 trials involving 3,664 children with ADHD that reported data on irritability as a side effect. The relative risk of irritability significantly differed between psychostimulant classes (test for subgroup differences.2 1 = 7.6, P =.006). Methylphenidate derivatives were associated with a significantly decreased risk of irritability compared to placebo (risk ratio [RR] = 0.89 [95% CI, 0.82 to 0.96], z = -2.87, P =.004, k = 32, I2 = 50%), whereas amphetamine derivatives were associated with a significantly increased risk of irritability (RR = 2.90 [95% CI, 1.26 to 6.71], z = 2.5, P =.01, k = 5, I2 = 0%). Conclusions: This meta-analysis suggests an increased risk of irritability may be confined to amphetamine-derived psychostimulants. Future meta-analyses examining the effects of amphetamine and methylphenidate derivatives on irritability as a continuous measure, as well as head-to-head trials between methylphenidate and amphetamine derivatives examining effects on irritability, will be important to replicate the findings of this meta-analysis. (C) Copyright 2017 Physicians Postgraduate Press, Inc.
dc.description.indexMEDLINE
dc.description.sponsorshipNational Institutes of Health (NIH) [1K23MH091240]
dc.description.sponsorshipTourette Syndrome Association
dc.description.sponsorshipNARSAD
dc.description.sponsorshipPatterson Foundation
dc.description.sponsorshipNational Center for Research Resources, a component of the National Institutes of Health [UL1 RR024139]
dc.description.sponsorshipNIH roadmap for Medical Research
dc.identifier.citationJOURNAL OF CLINICAL PSYCHIATRY, v.78, n.6, p.E648-E655, 2017
dc.identifier.doi10.4088/JCP.15r10601
dc.identifier.eissn1555-2101
dc.identifier.issn0160-6689
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/22093
dc.language.isoeng
dc.publisherPHYSICIANS POSTGRADUATE PRESS
dc.relation.ispartofJournal of Clinical Psychiatry
dc.rightsrestrictedAccess
dc.rights.holderCopyright PHYSICIANS POSTGRADUATE PRESS
dc.subject.otherattention-deficit/hyperactivity-disorder
dc.subject.otherdeficit hyperactivity disorder
dc.subject.otherplacebo-controlled evaluation
dc.subject.otherextended-release capsules
dc.subject.otherdouble-blind
dc.subject.otherlisdexamfetamine dimesylate
dc.subject.otherpreschool-children
dc.subject.otherclinical-efficacy
dc.subject.othercontrolled-trial
dc.subject.othermethylphenidate
dc.subject.wosPsychology, Clinical
dc.subject.wosPsychiatry
dc.titleRisk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalSTUCKELMAN, Zachary D.:Yale Child Study Ctr, New Haven, CT USA
hcfmusp.author.externalMULQUEEN, Jilian M.:Yale Child Study Ctr, New Haven, CT USA
hcfmusp.author.externalCOHEN, Stephanie C.:Yale Child Study Ctr, New Haven, CT USA
hcfmusp.author.externalCOUGHLIN, Catherine G.:Yale Child Study Ctr, New Haven, CT USA
hcfmusp.author.externalLECKMAN, James F.:Yale Child Study Ctr, New Haven, CT USA
hcfmusp.author.externalBLOCH, Michael H.:Yale Child Study Ctr, New Haven, CT USA; Yale Univ, Dept Psychiat, New Haven, CT 06520 USA
hcfmusp.citation.scopus28
hcfmusp.contributor.author-fmusphcEDUARDO FERRACIOLI ODA
hcfmusp.description.beginpageE648
hcfmusp.description.endpageE655
hcfmusp.description.issue6
hcfmusp.description.volume78
hcfmusp.origemWOS
hcfmusp.origem.pubmed28682529
hcfmusp.origem.scopus2-s2.0-85025085173
hcfmusp.origem.wosWOS:000410095200005
hcfmusp.publisher.cityMEMPHIS
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAHMANN PA, 1993, PEDIATRICS, V91, P1101
hcfmusp.relation.referenceAmerican Psychiatric Association,, 2013, DIAGNOSTIC STAT MANU
hcfmusp.relation.referenceArnold L. E., 2000, J ATTEN DISORD, V3, P200, DOI 10.1177/108705470000300403
hcfmusp.relation.referenceBARKLEY RA, 1990, PEDIATRICS, V86, P184
hcfmusp.relation.referenceBiederman J, 2007, CLIN THER, V29, P450, DOI 10.1016/j.clinthera.2007.03.006
hcfmusp.relation.referenceBrotman MA, 2006, BIOL PSYCHIAT, V60, P991, DOI 10.1016/j.biopsych.2006.08.042
hcfmusp.relation.referenceBuitelaar JK, 1996, J CHILD PSYCHOL PSYC, V37, P587, DOI 10.1111/j.1469-7610.1996.tb01445.x
hcfmusp.relation.referenceChildress AC, 2009, J CHILD ADOL PSYCHOP, V19, P351, DOI 10.1089/cap.2009.0007
hcfmusp.relation.referenceCoccaro EF, 2015, CNS SPECTRUMS, V20, P295, DOI 10.1017/S1092852915000310
hcfmusp.relation.referenceCONNERS CK, 1980, ARCH GEN PSYCHIAT, V37, P922
hcfmusp.relation.referenceConnor DF, 2002, J AM ACAD CHILD PSY, V41, P253, DOI 10.1097/00004583-200203000-00004
hcfmusp.relation.referenceCROWLEY TJ, 1972, PSYCHOPHARMACOLOGIA, V27, P213, DOI 10.1007/BF00422801
hcfmusp.relation.referencede Almeida RMM, 2005, EUR J PHARMACOL, V526, P51, DOI 10.1016/j.ejphar.2005.10.004
hcfmusp.relation.referencede la Cruz L Fernandez, 2015, J AM ACAD CHILD ADOL, V54
hcfmusp.relation.referenceDougherty DD, 2006, DEPRESS ANXIETY, V23, P175, DOI 10.1002/da.20168
hcfmusp.relation.referenceDURING MJ, 1992, NEUROSCI LETT, V140, P129, DOI 10.1016/0304-3940(92)90698-7
hcfmusp.relation.referenceEfron D, 1997, PEDIATRICS, V100, P662, DOI 10.1542/peds.100.4.662
hcfmusp.relation.referenceFerrari PF, 2003, EUR J NEUROSCI, V17, P371, DOI 10.1046/j.1460-9568.2003.02447.x
hcfmusp.relation.referenceFindling RL, 2006, EUR CHILD ADOLES PSY, V15, P450, DOI 10.1007/s00787-006-0565-0
hcfmusp.relation.referenceFindling RL, 2011, J AM ACAD CHILD PSY, V50, P395, DOI 10.1016/j.jaac.2011.01.007
hcfmusp.relation.referenceFirestone P, 1998, J CHILD ADOL PSYCHOP, V8, P13, DOI 10.1089/cap.1998.8.13
hcfmusp.relation.referenceFITZPATRICK PA, 1992, J AM ACAD CHILD PSY, V31, P226, DOI 10.1097/00004583-199203000-00008
hcfmusp.relation.referenceFleckenstein AE, 1999, EUR J PHARMACOL, V382, P45, DOI 10.1016/S0014-2999(99)00588-9
hcfmusp.relation.referenceGadow KD, 2014, J AM ACAD CHILD ADOL, V53
hcfmusp.relation.referenceGadow KD, 2014, J AM ACAD CHILD ADOL, V53, pe1
hcfmusp.relation.referenceGITTELMANKLEIN R, 1976, ARCH GEN PSYCHIAT, V33, P1217
hcfmusp.relation.referenceGorman EB, 2006, J AM ACAD CHILD PSY, V45, P808, DOI 10.1097/01.chi.0000214191.57993.dd
hcfmusp.relation.referenceGREENBERG LM, 1972, AM J PSYCHIAT, V129, P532
hcfmusp.relation.referenceGreenhill LL, 2006, J AM ACAD CHILD PSY, V45, P817, DOI 10.1097/01.chi.0000220847.41027.5d
hcfmusp.relation.referenceGreenhill LL, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.3.e39
hcfmusp.relation.referenceHarpin VA, 2005, ARCH DIS CHILD, V90, pI2, DOI 10.1136/adc.2004.059006
hcfmusp.relation.referenceHess EJ, 1996, J NEUROSCI, V16, P3104
hcfmusp.relation.referenceKANTAK KM, 1988, PSYCHOPHARMACOLOGY, V96, P468, DOI 10.1007/BF02180026
hcfmusp.relation.referenceKLORMAN R, 1990, J AM ACAD CHILD PSY, V29, P702, DOI 10.1097/00004583-199009000-00005
hcfmusp.relation.referenceKuczenski R, 1997, J NEUROCHEM, V68, P2032
hcfmusp.relation.referenceLee J, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-70
hcfmusp.relation.referenceMICZEK KA, 1974, PSYCHOPHARMACOLOGIA, V39, P275, DOI 10.1007/BF00422968
hcfmusp.relation.referenceNewcorn JH, 2008, AM J PSYCHIAT, V165, P721, DOI 10.1176/appi.ajp.2007.05091676
hcfmusp.relation.referencePappadopulos E, 2006, J CAN ACAD CHILD ADO, V15, P27
hcfmusp.relation.referencePliszka SR, 2000, J AM ACAD CHILD PSY, V39, P619, DOI 10.1097/00004583-200005000-00016
hcfmusp.relation.referenceRAPOPORT JL, 1974, ARCH GEN PSYCHIAT, V30, P789
hcfmusp.relation.referenceRAPPORT MD, 1985, J ABNORM CHILD PSYCH, V13, P227, DOI 10.1007/BF00910644
hcfmusp.relation.referenceSafer Daniel J, 2009, Child Adolesc Psychiatry Ment Health, V3, P35, DOI 10.1186/1753-2000-3-35
hcfmusp.relation.referenceSchachar R, 2008, J CHILD ADOL PSYCHOP, V18, P11, DOI 10.1089/cap.2007.0039
hcfmusp.relation.referenceSchulz E, 2010, J CHILD ADOL PSYCHOP, V20, P377, DOI 10.1089/cap.2009.0106
hcfmusp.relation.referenceShaw P, 2014, AM J PSYCHIAT, V171, P276, DOI 10.1176/appi.ajp.2013.13070966
hcfmusp.relation.referenceSolanto M, 2009, J CHILD ADOL PSYCHOP, V19, P663, DOI 10.1089/cap.2009.0033
hcfmusp.relation.referenceStein MA, 2003, PEDIATRICS, V112, pE404, DOI 10.1542/peds.112.5.e404
hcfmusp.relation.referenceStein MA, 1996, PEDIATRICS, V98, P748
hcfmusp.relation.referenceStringaris A, 2009, J CHILD PSYCHOL PSYC, V50, P216, DOI 10.1111/j.1469-7610.2008.01989.x
hcfmusp.relation.referenceSwanson JM, 2004, PEDIATRICS, V113, pE206, DOI 10.1542/peds.113.3.e206
hcfmusp.relation.referenceSwenson M, STIMULANT EQUIVALENC
hcfmusp.relation.referenceWERRY JS, 1980, J CHILD PSYCHOL PSYC, V21, P27, DOI 10.1111/j.1469-7610.1980.tb00013.x
hcfmusp.relation.referenceWERRY JS, 1974, AUST NZ J PSYCHIAT, V8, P9, DOI 10.3109/00048677409159770
hcfmusp.relation.referenceWigal Sharon B, 2009, Child Adolesc Psychiatry Ment Health, V3, P17, DOI 10.1186/1753-2000-3-17
hcfmusp.relation.referenceWigal T, 2006, J AM ACAD CHILD PSY, V45, P1294, DOI 10.1097/01.chi.0000235082.63156.27
hcfmusp.relation.referenceWilens TE, 2010, J CLIN PSYCHIAT, V71, P548, DOI 10.4088/JCP.09m05779pur
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicatione57fe67c-0f39-40b0-8534-22e379a556eb
relation.isAuthorOfPublication.latestForDiscoverye57fe67c-0f39-40b0-8534-22e379a556eb
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC